ACLX

Arcellx, Inc.

67.08 USD
-0.54 (-0.80%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arcellx, Inc. stock is up 4.18% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 2 February’s closed higher than January. In the last 3 Unusual Options Trades, there were 3 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
28 Dec 16:04 19 Jan, 2024 60.00 CALL 159 1486
29 Jan 19:42 16 Feb, 2024 50.00 CALL 25 299
08 Feb 18:38 16 Feb, 2024 50.00 CALL 25 321

About Arcellx, Inc.

Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.